LEXXW News and Press, Lexaria Bioscience Corp. Warrant From 05/17/24

--News Direct-- Study WEIGHT-A24-1 will evaluate DehydraTECH-processed pure semaglutide and liraglutide Will DehydraTECH processing result in higher brain absorption of GLP-1 drugs? Kelowna, British Columbia – May 17, 2024 – TheNewswire – Lexaria Biosc...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs m...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway and the first dosing visit for all nine study participants has concluded. The three-arm, crossover study will compare three 7 mg se...

(TheNewswire) Kelowna, British Columbia – May 8, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that human pilot study...

KELOWNA, BC / ACCESSWIRE / May 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study part...

KELOWNA, BC / ACCESSWIRE / May 6, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces an applied research program to evaluate certain molecular characteristics of DehydraTECH processed with the glucagon...

KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain...

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 stu...

(TheNewswire) Human Pilot Study #2 (GLP-1-H24-2) Approved Kelowna, British Columbia – TheNewswire – April 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&...